- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07706543
Evaluation of a French Hospital Discharge Therapeutic Education Program by Nurses for Heart Failure Patient (EduSor) (EDUSOR)
Evaluation of a Therapeutic Patient Education Program for Discharge (ETPsh) by Nurses in a French Hospital Setting Among Patients With Heart Failure
Heart failure affects 2.3% of the adult French population. Readmission within 30 days doubles the risk of early death within the following 30 to 60 days, as well as the risk of rehospitalization over the subsequent two years. Incorporating nurse-led discharge education can significantly reduce readmissions for heart failure as well as all-cause readmissions. Drawing on practices from English-speaking countries and Switzerland regarding patient discharge education at hospital, we propose to evaluate a discharge education program in the French hospital setting for patients with heart failure.
The objective of this multicenter before-and-after study is to evaluate the impact of a nurse-led discharge education delivered at hospital on the quality of the care pathway for patients with heart failure, assessed 30 days after hospital discharge. The primary outcome is the reduction in 30-day unplanned all-cause hospital readmissions, including emergency department visits. An informal (non-professional) caregiver may also be enrolled in the study if identified by the patient and present during the hospitalization.
Patients enrolled before implementation of the discharge education will constitute the control group (standard therapeutic patient education group). They will receive usual hospital care, including educational sessions throughout hospitalization covering the disease, treatments, and self-care, as well as a follow-up consultation with a nurse 30 days after hospital discharge. This usual care is referred to as standard therapeutic patient education and does not include a structured therapeutic patient education intervention at hospital discharge.
Patients receiving the discharge education will constitute the intervention group (standard therapeutic patient education with discharge education group). They will receive the same usual care (i.e., standard therapeutic patient education and the 30-day post-discharge nurse follow-up consultation), supplemented by the nurse-led discharge education intervention during their hospitalization.
To minimize the risk of contamination (diffusion bias), the control group will be enrolled and complete follow-up before nurses receive training in the discharge education intervention.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Patients and their informal caregivers will be informed about the study by the nursing staff within the first two days of hospitalization in the cardiology departments participating in the study. Their eligibility will then be assessed, and eligible patients and caregivers will be invited to participate. A participant information sheet describing the study will be provided and explained to both the patient and the informal caregiver.
Patients and their informal caregivers will be given a 24-hour reflection period. After this period, they will have the opportunity to discuss any remaining questions with the investigator nurse, who will provide any necessary clarification. Patients and informal caregivers who agree to participate will then sign the informed consent form and be enrolled in the study. The investigator will also sign the informed consent form.
All participants in the control group will be enrolled simultaneously across the three participating study centers. The same enrollment procedure will be followed for the intervention group.
Patients in the intervention group will receive an initial educational assessment on the day following enrollment, a participatory therapeutic education session using the teach-back method within the 24 hours preceding hospital discharge, a follow-up telephone call from a nurse 7 days after discharge, and a final educational assessment at the routine 30-day post-discharge follow-up visit. Whenever possible, the patient's informal caregiver will be asked to accompany the patient to this follow-up consultation.
A participant may be prematurely withdrawn from the study for any of the following reasons:
- an intercurrent disease interfering with the normal conduct of the study protocol;
- death;
- participant's decision
- a major protocol deviation;
- loss to follow-up (a participant is considered lost to follow-up if they fail to attend a scheduled study visit and no information regarding their status can be obtained despite all reasonable efforts to contact them and determine the reason for study discontinuation. The reason "lost to follow-up" will only be assigned after these efforts have been unsuccessful).
Patients and their informal caregivers may participate in another clinical study provided that, in the opinion of the investigator, such participation does not interfere with the conduct or objectives of the present study. Participants must therefore inform the investigator of any concurrent participation in another study, and the investigator will determine whether simultaneous participation is appropriate.
The study may be temporarily suspended or permanently terminated for any of the following reasons:
- insufficient or no participant recruitment;
- inability to secure funding for the study;
- any directive issued by the competent regulatory authorities requiring the temporary suspension or permanent termination of the study;
- a decision by the sponsor and the coordinating investigator.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Lise Laclautre
- Telefoonnummer: 0473754963
- E-mail: promo_interne_drci@chu-clermontferrand.fr
Studie Locaties
-
-
-
Clermont-Ferrand, Frankrijk
- CHU clermont-ferrand
-
Contact:
- Sarah LAROCHE
- Telefoonnummer: +33473754320
- E-mail: slaroche@chu-clermontferrand.fr
-
Hoofdonderzoeker:
- Sarah LAROCHE
-
Poitiers, Frankrijk
- CHU Poitiers
-
Contact:
- Alexandra MARTIN
- Telefoonnummer: +33549444418
- E-mail: alexandra.martin@chu-poitiers.fr
-
Hoofdonderzoeker:
- Alexandra MARTIN
-
Vichy, Frankrijk
- CH VICHY
-
Contact:
- Claude LAGRANGE
- Telefoonnummer: +33470310762
- E-mail: claude.lagrange@ch-vichy.fr
-
Hoofdonderzoeker:
- Claude LAGRANGE
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Patient aged 18 years old or more,
- Fluent in spoken and written French,
- Willing to participate in the study,
- Hospitalized for heart failure in one of the participating centers for at least 2 days,
- Affiliated with a French social security scheme
- Discharged either to home or transferred to a Medical and Rehabilitation Care unit.
Exclusion Criteria:
- Hospitalized for a reason other than heart failure,
- Previously included in the study during a prior hospitalization,
- Presenting with identified cognitive impairment,
- In a situation deemed inappropriate by the care team (end of life),
- Living in an institutional setting,
- Pregnant women,
- Breastfeeding women,
- Under legal protective measures,
- Enrolled in another interventional research study that may interfere with the results of the present study, according to the investigator's judgment.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ondersteunende zorg
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Geen tussenkomst: Standard therapeutic patient education group
Participants in the control group will receive usual care in the cardiology department. The multidisciplinary usual care involves both medical professionals (including cardiologists and pharmacists) and allied health professionals (including advanced practice nurses, registered nurses, dietitians, and physical activity specialists). Usual care is integrated into the heart failure care pathway, ensuring continuity between community-based and hospital care, hospitalization, and ongoing management at home. During hospitalization, participants will receive standard therapeutic patient education as well as a routine nurse-led follow-up consultation 30 days after hospital discharge. Patients will also receive the standard discharge documents, together with the usual information and advice provided at discharge. |
|
|
Experimenteel: Discharge education group
Participants will receive usual care (as described for the control group), supplemented by a structured discharge education intervention delivered by research nurses trained in therapeutic patient education.
|
The intervention includes :
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Unplanned all-cause rehospitalizations, including emergency department visits.
Tijdsspanne: At 30 days after hospital discharge
|
Rehospitalization is defined as "an unplanned hospital stay of at least one overnight stay"
|
At 30 days after hospital discharge
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Unplanned rehospitalizations, including emergency department visits, for heart failure.
Tijdsspanne: At 30 days after hospital discharge
|
Rehospitalizations are assessed using the European Society of Cardiology definition of hospitalization for heart failure.
Those that meet the criteria of this definition are classified as heart failure-related readmissions.
|
At 30 days after hospital discharge
|
|
Patient death
Tijdsspanne: At 30 days after hospital discharge
|
At 30 days after hospital discharge
|
|
|
Patient satisfaction of the hospital discharge organization
Tijdsspanne: At 30 days after hospital discharge
|
Score on the "Hospital Discharge Organization" dimension of the French National Authority for Health "e-Satis+48h MCO" questionnaire, a national patient satisfaction and experience self-administrated questionnaire for hospitalized patients
|
At 30 days after hospital discharge
|
|
Scheduled rehospitalizations that were not completed.
Tijdsspanne: At 30 days after hospital discharge
|
At 30 days after hospital discharge
|
|
|
Number of consultations with the patient's primary care physician.
Tijdsspanne: At 30 days after hospital discharge
|
At 30 days after hospital discharge
|
|
|
Scheduling of a cardiology consultation (appointment made).
Tijdsspanne: At 30 days after hospital discharge
|
At 30 days after hospital discharge
|
|
|
Daily adherence to cardiovascular medication
Tijdsspanne: At baseline
|
Measurement of cardiovascular medication adherence using the self-administered MASCARD questionnaire
|
At baseline
|
|
Daily adherence to cardiovascular medication
Tijdsspanne: At 30 days after hospital discharge
|
Measurement of cardiovascular medication adherence using the self-administered MASCARD questionnaire
|
At 30 days after hospital discharge
|
|
Number of warning signs and self-care behaviors cited by the patient.
Tijdsspanne: At 30 days after hospital discharge
|
Warning signs : Shortness of breath - Rapid weight gain - Lower limb edema - Fatigue Sel-care behaviors: Physical activity - Weighing oneself - Medication adherence - Avoiding added salt
|
At 30 days after hospital discharge
|
|
Heart failure self-care behaviors
Tijdsspanne: At baseline
|
Assessed using the European Heart Failure Self-Care Behaviour Scale-9 (EHFScB-9) self-administered questionnaire
|
At baseline
|
|
Heart failure self-care behaviors
Tijdsspanne: At 30 days after hospital discharge
|
Assessed using the European Heart Failure Self-Care Behaviour Scale-9 (EHFScB-9) self-administered questionnaire
|
At 30 days after hospital discharge
|
|
Completeness rate of remote monitoring data transmission for patients enrolled in telemonitoring
Tijdsspanne: At 30 days after hospital discharge
|
Weight, blood pressure, oxygen saturation
|
At 30 days after hospital discharge
|
|
Number of alerts and number of medically managed alerts, generated through remote monitoring for patients enrolled in telemonitoring
Tijdsspanne: At 30 days after hospital discharge
|
At 30 days after hospital discharge
|
|
|
Self-perceived patient competence in disease management
Tijdsspanne: At baseline
|
Assessed using a 0-5 "skills star" scale (management of medications, management of follow-up appointments, recognition of warning signs, and implementation of self-care behaviors).
|
At baseline
|
|
Self-perceived patient competence in disease management
Tijdsspanne: At 30 days after hospital discharge
|
Assessed using a 0-5 "skills star" scale (management of medications, management of follow-up appointments, recognition of warning signs, and implementation of self-care behaviors).
|
At 30 days after hospital discharge
|
|
Self-perceived patient competence in contacting and alerting the care team when experiencing difficulties in their care pathway
Tijdsspanne: At baseline
|
Assessed using a 0-5 "skills star" scale (communication with healthcare professionals).
|
At baseline
|
|
Self-perceived patient competence in contacting and alerting the care team when experiencing difficulties in their care pathway
Tijdsspanne: At 30 days after hospital discharge
|
Assessed using a 0-5 "skills star" scale (communication with healthcare professionals).
|
At 30 days after hospital discharge
|
|
Anxiety and depression of patients
Tijdsspanne: At baseline
|
Assessed using the self-administrated Hospital Anxiety and Depression Scale (HADS).
|
At baseline
|
|
Anxiety and depression of patients
Tijdsspanne: At 30 days after hospital discharge
|
Assessed using the self-administrated Hospital Anxiety and Depression Scale (HADS).
|
At 30 days after hospital discharge
|
|
Informal caregiver burden
Tijdsspanne: At baseline
|
Assessed using the Mini-Zarit self-administered questionnaire.
|
At baseline
|
|
Informal caregiver burden
Tijdsspanne: At 30 days after hospital discharge
|
Assessed using the Mini-Zarit self-administered questionnaire.
|
At 30 days after hospital discharge
|
|
Cost-effectiveness and budget impact medico-economic analysis of discharge education.
Tijdsspanne: At 30 days after hospital discharge
|
Incremental cost-effectiveness ratio of discharge education and the bundled payment amount compatible with the financial sustainability of discharge education.
|
At 30 days after hospital discharge
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Marie Sophie CHERILLAT, University Hospital, Clermont-Ferrand
Publicaties en nuttige links
Algemene publicaties
- Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res. 2002 Feb;52(2):69-77. doi: 10.1016/s0022-3999(01)00296-3.
- Zannad F, Garcia AA, Anker SD, Armstrong PW, Calvo G, Cleland JG, Cohn JN, Dickstein K, Domanski MJ, Ekman I, Filippatos GS, Gheorghiade M, Hernandez AF, Jaarsma T, Koglin J, Konstam M, Kupfer S, Maggioni AP, Mebazaa A, Metra M, Nowack C, Pieske B, Pina IL, Pocock SJ, Ponikowski P, Rosano G, Ruilope LM, Ruschitzka F, Severin T, Solomon S, Stein K, Stockbridge NL, Stough WG, Swedberg K, Tavazzi L, Voors AA, Wasserman SM, Woehrle H, Zalewski A, McMurray JJ. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. Eur J Heart Fail. 2013 Oct;15(10):1082-94. doi: 10.1093/eurjhf/hft095. Epub 2013 Jun 19.
- Higginson IJ, Gao W, Jackson D, Murray J, Harding R. Short-form Zarit Caregiver Burden Interviews were valid in advanced conditions. J Clin Epidemiol. 2010 May;63(5):535-42. doi: 10.1016/j.jclinepi.2009.06.014.
- Oh EG, Lee HJ, Yang YL, Kim YM. Effectiveness of Discharge Education With the Teach-Back Method on 30-Day Readmission: A Systematic Review. J Patient Saf. 2021 Jun 1;17(4):305-310. doi: 10.1097/PTS.0000000000000596.
- McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368. No abstract available.
- Lambrinou E, Kalogirou F, Lamnisos D, Sourtzi P. Effectiveness of heart failure management programmes with nurse-led discharge planning in reducing re-admissions: a systematic review and meta-analysis. Int J Nurs Stud. 2012 May;49(5):610-24. doi: 10.1016/j.ijnurstu.2011.11.002. Epub 2011 Dec 22.
- Manning S. Bridging the gap between hospital and home: a new model of care for reducing readmission rates in chronic heart failure. J Cardiovasc Nurs. 2011 Sep-Oct;26(5):368-76. doi: 10.1097/JCN.0b013e318202b15c.
- Paul S. Hospital discharge education for patients with heart failure: what really works and what is the evidence? Crit Care Nurse. 2008 Apr;28(2):66-82. No abstract available.
- Hill CA. Acute heart failure: too sick for discharge teaching? Crit Care Nurs Q. 2009 Apr-Jun;32(2):106-11. doi: 10.1097/CNQ.0b013e3181a27ccd.
- Albano MG, Gagnayre R, de Andrade V, d'Ivernois JF. L'education precedant la sortie de l'hopital : nouvelle forme d'education therapeutique. Criteres de qualite et perspectives d'application a notre contexte. Rech Soins Infirm. 2020;141(2):70-77. doi: 10.3917/rsi.141.0070. French.
- Koelling TM, Johnson ML, Cody RJ, Aaronson KD. Discharge education improves clinical outcomes in patients with chronic heart failure. Circulation. 2005 Jan 18;111(2):179-85. doi: 10.1161/01.CIR.0000151811.53450.B8. Epub 2005 Jan 10.
- Oh EG, Lee HJ, Yang YL, Lee S, Kim YM. Development of a discharge education program using the teach-back method for heart failure patients. BMC Nurs. 2021 Jun 24;20(1):109. doi: 10.1186/s12912-021-00622-2.
- Baldewijns K, Boyne J, Rohde C, de Maesschalck L, Deville A, Brandenburg V, De Bleser L, Derickx M, Bektas S, Brunner-La Rocca HP. What kind of patient education and self-care support do patients with heart failure receive, and by whom? Implementation of the ESC guidelines for heart failure in three European regions. Heart Lung. 2023 Jan-Feb;57:25-30. doi: 10.1016/j.hrtlng.2022.07.013. Epub 2022 Aug 19.
- Mattina K, Dabney BW, Linton M. The Impact of Nurse Education on Heart Failure Readmissions and Patient Education. J Dr Nurs Pract. 2021 Jan 19:JDNP-D-19-00076. doi: 10.1891/JDNP-D-19-00076. Online ahead of print.
- Boisvert S, Francoeur J, Gallani MC. Cross-Cultural Adaptation and Reliability of the French-Canadian Version of the European Heart Failure Self-Care Behaviour Scale-9. J Nurs Meas. 2019 Dec 1;27(3):458-477. doi: 10.1891/1061-3749.27.3.458.
- Martin-Latry K, Latry P, Pucheu Y, Couffinhal T. [Hospital medication adherence scale development in cardiovascular disorders]. Ann Pharm Fr. 2021 Jul;79(4):457-464. doi: 10.1016/j.pharma.2020.11.008. Epub 2020 Dec 10. French.
- Pellet J, Weiss M, Zuniga F, Mabire C. Improving patient activation with a tailored nursing discharge teaching intervention for multimorbid inpatients: A quasi-experimental study. Patient Educ Couns. 2024 Jan;118:108024. doi: 10.1016/j.pec.2023.108024. Epub 2023 Oct 18.
- Tuppin P, Cuerq A, de Peretti C, Fagot-Campagna A, Danchin N, Juilliere Y, Alla F, Allemand H, Bauters C, Drici MD, Hagege A, Jondeau G, Jourdain P, Leizorovicz A, Paccaud F. First hospitalization for heart failure in France in 2009: patient characteristics and 30-day follow-up. Arch Cardiovasc Dis. 2013 Nov;106(11):570-85. doi: 10.1016/j.acvd.2013.08.002. Epub 2013 Oct 18.
- Mowery BD, Brand E, Gisila D, Healy K, Mannaye TA, Bhuvanesh A, Babb R, Bettencourt AP, McLaughlin MK, Russell-Babin K. Improving Discharge Education and Outcomes for Patients with Heart Failure. Am J Nurs. 2025 Mar 1;125(3):40-46. doi: 10.1097/AJN.0000000000000030. Epub 2025 Feb 20.
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- PHRIP 2024 CHERILLAT
- 2025-A02457-42 (Andere identificatie: ANSM)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .